DUBLIN, March 13, 2019 /PRNewswire/ -- The "Pharmacogenomics Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The market is projected to grow at a CAGR of 6.18% during the forecast period.
The propelling factors for the growth of the pharmacogenomics market include the increased expenditure in R&D and an increase in the rate of adverse reactions, which has led to the higher adoption of pharmacogenomics in the global market. The increasing focus on precision medicine, along with the need to enhance drug safety and efficacy, is also further fuelling the growth of this market.
The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the goal of the precision medicine approach is to integrate genetic and environmental information of particular diseases and/or their responses to particular treatments. This is done to determine or assist in targeted drug therapies, as well as in treatment procedures to be adopted to minimize the side effects and improve results, which will require pharmacogenomics extensively.
For instance, in the United States, in 2015, the government announced a new precision medicine initiative to accelerate progress toward individualized care that takes genetic variability into account for various chronic disorders.
Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients, and at the same time, has found to reduce the unnecessary cost due to unresponsive treatment by patients. Hence, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, hence, driving the market growth during the forecast period.
The increasing expenditure in R&D and an increase in the rate of adverse reactions have led to the higher adoption of pharmacogenomics in the global market. Furthermore, there is a rapid increase in the number of research studies related to sequencing, especially next-generation sequencing, which is expected to increase the demand for pharmacogenomic tests in the future.
Key Market Trends
Drug Discovery is the Segment under Application that is Expected to Grow the Fastest during the Forecast Period
Pharmacogenomics is one of the major emerging trends in the field of medical science, which greatly influences the drug development process. With the use of pharmacogenomics, target identification by drugs has become relatively easy, which ensures much higher chances of success for the approval of drugs. In addition, out of 500 genes, only 50 disease genes have drug availability in the market today. This emphasizes the market opportunity in the future for different manufacturers to concentrate on drug discovery using pharmacogenomics.
Pharmacogenomics has also found applications in the treatment of cancer patients, by anticipating the possible differences in drug response, resistance, efficacy, and toxicity of the chemotherapeutic and targeted immune biologic agents. Therefore, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, which has helped in the growth of the oncology segment of the market studied.
North America holds the Largest Share of the Market and is Expected to Follow the Same Trend over the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period, due to the presence of high per capita healthcare expenditure, coupled with high patient awareness levels, and the high prevalence of target diseases. Moreover, the increasing preference for personalized treatment, along with its high adoption rate, is further contributing to the growth of the market.
The large interest of researchers and investment in the safety and efficiency of drugs by companies are one the major factors responsible for the growth of the market. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Focus on Precision Medicine
4.2.2 Increasing Expenditure in R&D
4.2.3 High Rate of Adverse Drug Reaction
4.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D
4.3 Market Restraints
4.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response
4.3.2 Reimbursement Issues
4.4 Porter's Five Forces Analysis
5 Market Segmentation
5.1 By Technology
5.1.1 DNA Sequencing
5.1.3 Polymerase Chain Reaction
5.1.5 Mass Spectrometry
5.1.6 Other Technologies
5.2 By Application
5.2.1 Drug Discovery
5.2.4 Pain Management
5.2.5 Other Applications
5.3.1 North America
5.3.4 Middle East & Africa
5.3.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bayer AG
6.1.5 Becton, Dickinson and Company
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 F. Hoffmann-La Roche Ltd.
6.1.8 Illumina Inc.
6.1.10 Thermo Fisher Scientific Inc.
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/n77n64/pharmacogenomics?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets